RecruitingPhase 1NCT04925492

PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD

Positron Emission Tomography (PET) Imaging of Vaso-occlusive Crisis(VOC) in Sickle Cell Disease (SCD).


Sponsor

Enrico Novelli

Enrollment

20 participants

Start Date

Nov 11, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to find objective biomarkers of vaso-occlusion (blood vessel blockage) in people with SCD. Using information from earlier studies and work being done, researchers have developed a strategy to image VOC, using positron emission tomography (PET). The ability to see and measure VOC in SCD patients can help patient care, by showing when and how a VOC is occurring or going to occur. Studying this method will also help in future drug research, as it will allow researchers to deliver promising new medications that target hyper-adhesion and sickling in people with SCD.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cu-64]-LLP2A and Positron Emission Tomography for people with sickle cell disease. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONPositron Emission Tomography

An imaging method that uses radiotracers to view changes in the metabolic process.

DRUGCu-64]-LLP2A

A radioactive tracer used in PET imaging.


Locations(1)

UPMC

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04925492


Related Trials